Latest filing published 29 Apr 2019 for Anixa Biosciences Inc, €7,528.
No signal scores available.
Based on 32 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Filings by David Cavalier span 2 companies, the busiest being Aeolus Pharmaceuticals, Inc. and Anixa Biosciences Inc. Between 30 January 2008 and 29 April 2019, the trades on record add up to 82 filings.
Purchases make up the whole of the open-market record (64 purchases, €3.6M). The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant. So far in 2019, the count stands at 1 purchase and no sales.
The median purchase comes to €2,705. After 32 purchases with a full 90-day history, the hit rate stands at 47% and the median 90-day move at +0.0%. They describe history only and say nothing certain about the share price ahead.
The record was last updated on 29 April 2019 with an open-market purchase (€7,528) in Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 41 declarations